Compare BV & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BV | IMTX |
|---|---|---|
| Founded | 1939 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2018 | N/A |
| Metric | BV | IMTX |
|---|---|---|
| Price | $12.80 | $10.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $14.63 | ★ $19.25 |
| AVG Volume (30 Days) | ★ 654.8K | 564.1K |
| Earning Date | 02-04-2026 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $2,672,800,000.00 | $99,445,031.00 |
| Revenue This Year | $3.75 | N/A |
| Revenue Next Year | $2.81 | $19.39 |
| P/E Ratio | $98.92 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.06 | $3.30 |
| 52 Week High | $17.11 | $12.41 |
| Indicator | BV | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 48.56 |
| Support Level | $12.64 | $9.96 |
| Resistance Level | $13.05 | $10.50 |
| Average True Range (ATR) | 0.27 | 0.42 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 62.44 | 49.50 |
BrightView Holdings Inc is a provider of commercial landscaping services in the United States. The company provides commercial landscaping services, landscape maintenance, and enhancements to tree care and landscape development. It operates through two segments namely Maintenance Services, and Development Services. The Maintenance Services are self-performed through a national branch network and are route-based in nature. It includes mowing, gardening, mulching and snow removal, water management etc. And Development Services are comprised of sophisticated design, coordination, and installation of landscapes at recognizable corporate, athletic, and university complexes. The company generates a majority of its revenue from Maintenance Services.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.